EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)

Richard B Warren, Lars E French, Andrew Blauvelt, Richard G Langley, Alexander Egeberg, Ulrich Mrowietz, Hamish J A Hunter, Melinda Gooderham, Per Soerensen, Philippe Andres, Morten O A Sommer, Anna Carlsson und 2 weitere

Journal of the American Academy of Dermatology · 2024

DOI: 10.1016/j.jaad.2023.11.005 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2024. Verfasst von Richard B Warren und 13 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom; NIHR Manchester Biomedical Research Centre, Manchester U…. Hauptthemen laut MEDLINE: Psoriasis, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Manchester Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Orismilast is a novel oral phosphodiesterase-4 (PDE4) B/D inhibitor being investigated as a potential treatment for moderate-to-severe psoriasis. OBJECTIVE: To evaluate efficacy and safety of orismilast modified-release formulation in moderate-to-severe psoriasis. METHODS: This multicenter, randomized (1:1:1:1 to 20, 30, 40 mg orismilast or placebo, twice daily), double-blinded, placebo-controlled, parallel-group, phase 2b, 16-week, dose-ranging study evaluated orismilast in adults with moderate-to-severe plaque psoriasis (NCT05190419). Efficacy end points were analyzed using multiple imputation. RESULTS: Of 202 randomized patients, baseline characteristics were balanced across arms, except greater severe disease proportions for orismilast vs placebo. Orismilast showed significant improvements in the primary end point, percentage change in Psoriasis Area and Severity Index (PASI), from baseline to week 16 (orismilast -52.6% to -63.7% and placebo, -17.3%; all P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisPhosphodiesterase 4 InhibitorsAdultHumansTreatment OutcomeSeverity of Illness IndexDouble-Blind Method

Stichwörter der Autor:innen

PDE4 inhibitorsPDE4BPDE4Doral administrationpsoriasistreatment efficacy

Substanzen

Phosphodiesterase 4 Inhibitors

Autor:innen und Institutionen

  • Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Cen…
  • Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University Munich, Munich, Germany; Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of M…
  • Oregon Medical Research Center, Portland, Oregon.
  • Division of Dermatology, Dalhousie University, Halifax, Canada.
  • Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany.

Förderung

  • Manchester Biomedical Research Centre

Zitieren

APA

Warren, R. B., French, L. E., Blauvelt, A., Langley, R. G., Egeberg, A., Mrowietz, U., Hunter, H. J. A., Gooderham, M., Soerensen, P., Andres, P., Sommer, M. O. A., Carlsson, A., Kjøller, K. D., & Strober, B. E. (2024). Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS). Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2023.11.005

Vancouver

Warren RB, French LE, Blauvelt A, Langley RG, Egeberg A, Mrowietz U, et al. Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS). Journal of the American Academy of Dermatology. 2024. doi:10.1016/j.jaad.2023.11.005

BibTeX
@article{Warren2024,
  author = {Warren, Richard B and French, Lars E and Blauvelt, Andrew and Langley, Richard G and Egeberg, Alexander and Mrowietz, Ulrich and Hunter, Hamish J A and Gooderham, Melinda and Soerensen, Per and Andres, Philippe and Sommer, Morten O A and Carlsson, Anna and Kjøller, Kim D and Strober, Bruce E},
  title = {Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)},
  journal = {Journal of the American Academy of Dermatology},
  year = {2024},
  doi = {10.1016/j.jaad.2023.11.005}
}
Kostenlos starten →